Physician profile
Harmit Singh
NPI 1891927430
$4,031.33
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,190 · 2020: $1,475 · 2021: $1,367.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $1,430.49 | 2019-2021 | |
| Alkermes, INC. | $716.38 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $577.24 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $469.66 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $255.87 | 2020-2021 | |
| Allergan, INC. | $237.98 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $112.89 | 2019-2021 | |
| Shire North American Group INC | $59.68 | 2019 | |
| Vertical Pharmaceuticals, LLC | $51.67 | 2019 | |
| Vanda Pharmaceuticals INC. | $40.49 | 2019 | |
| Ironshore Pharmaceuticals INC. | $33.00 | 2019 | |
| Lundbeck LLC | $26.54 | 2019 | |
| Jazz Pharmaceuticals INC. | $19.44 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harmit Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.